GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

2025-05-01 20:58:25 ET

GeoVax Labs, Inc. (GOVX)

Q1 2025 Earnings Conference Call

May 01, 2025 04:30 PM ET

Company Participants

Max Gadicke - Precision AQ, Investor Relations

David Dodd - Chairman, President & Chief Executive Officer

Mark Reynolds - Chief Financial Officer

Conference Call Participants

James Molloy - Alliance Global Partners

Robert LeBoyer - Noble Capital Markets

Jeffrey Kraws - Crystal Research Associates

Presentation

Operator

Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Mark Newman, PhD, Chief Scientific Officer; Kelly McKee, MD, MPH, Chief Medical Officer; and John Sharkey, PhD, Vice President, Business Development. [Operator Instructions] As a reminder, this conference is being recorded.

At this time, I’ll turn the call over to Max Gadicke of Precision AQ.

Max Gadicke

Thank you. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes. Actual results may differ materially from those included in these statements due to a variety of factors, including weather. GeoVax can develop and manufacture its product candidates with desired characteristics in a timely manner and such products will be safe for human use. GeoVax’s vaccines will effectively prevent targeted infections in humans. GeoVax’s product candidates will receive regulatory approvals necessary to be licensed and marketed. GeoVax raises required capital to complete development of its products.

There is development of competitive products that may be more effective or easier to use than GeoVax’s products. GeoVax will be able to enter into favorable manufacturing and distribution agreements and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax’ filings with the Securities and Exchange Commission, including those set forth at Risk Factors in GeoVax’s Form 10-K. It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.

David Dodd

Thank you. Welcome to the first quarter 2025 GeoVax Corporate Update Call. Following my comments, Mark Reynolds, our CFO, will provide an update of our financials, and then we will address any questions that you may have. We remain confident in the continued progress and compelling outlook for our portfolio of GEO-CM04S1, GEO-MVA, Gedeptin and the advanced MVA manufacturing process....

Read the full article on Seeking Alpha

For further details see: